Original language | English (US) |
---|---|
Pages (from-to) | 873-884 |
Number of pages | 12 |
Journal | American Journal of Cardiology |
Volume | 106 |
Issue number | 6 |
DOIs | |
State | Published - Sep 15 2010 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American Journal of Cardiology, Vol. 106, No. 6, 15.09.2010, p. 873-884.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - AJC Editor's consensus
T2 - Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk
AU - Friedewald, Vincent E.
AU - Bennett, Joel S.
AU - Christo, J. Paul
AU - Pool, James L.
AU - Scheiman, James M.
AU - Simon, Lee S.
AU - Strand, Vibeke
AU - White, William B.
AU - Williams, Gary W.
AU - Roberts, William C.
N1 - Funding Information: Dr. Friedewald has received honoraria for speaking from Novartis, East Hanover, New Jersey. Dr. Friedewald is a consultant for NicOx, Warren, New Jersey; and AstraZeneca, Wilmington, Delaware. Dr. Bennett is a member of the scientific advisory board of Polymedix, Inc., Radnor, Pennsylvania. Dr. Bennett is a consultant for Incyte Corporation, Wilmington, Pennsylvania; and Grant & Eisenhofer, PA, Wilmington, Delaware. Dr. Christo is a consultant for Acura Pharmaceuticals, Inc., Palatine, Illinois. Dr. Christo is a member of the advisory board of the Dannemiller Foundation, San Antonio, Texas. Dr. Scheiman is a consultant for AstraZeneca; Novartis Consumer Health, Parsippany, New Jersey; Pfizer; Bayer, West Haven, Connecticut; Takeda Pharmaceuticals, Skokie, Illinois; Pozen, Inc., Raleigh, North Carolina; NiCox, Sophia-Antipolis, France. Dr. Scheiman has received honoraria for speaking from AstraZeneca. Dr. Simon is a consultant for AAI Pharma, Wilmington, North Carolina; Affinergy, Research Triangle Park, North Carolina; AstraZeneca; AlphaRx, Markham, Ontario, Canada; Nuvo Research, Mississauga, Ontario, Canada; Roche, Basel, Switzerland; Pfizer; Novartis; PLx Pharma, Houston, Texas; Hisamatsu, Nishimachi, Japan; Cerimon, San Francisco, California; Leerink Swann, Boston, Massachusetts; Nitec, Reinach, Switzerland; Bayer; Rigel, South San Francisco, California; Chelsea, Charlotte, North Carolina; Regeneron, Tarrytown, New York; Cypress Biosciences, San Diego, California; Savient, East Brunswick, New Jersey; NiCox; Biocryst, Birmingham, Alabama; Wyeth, Madison, New Jersey; Solace, Cambridge, Massachusetts; Puretechventures and Puretech Development, Boston, Massachusetts; White Mountain Pharma, Lebanon, New Hampshire; TAP, Cambridge, Massachusetts; Abbott Laboratories, Abbott Park, Illinois; Cell Therapeutics, Memphis, Tennessee; Omeros, Seattle, Washington; Jazz, Palo Alto, California; Takeda Pharmaceuticals, Osaka, Japan; Teva, Petah Tikva, Israel; Zydus, Princeton, New Jersey; Proprius, San Diego, California; Sepracor, Marlborough, Massachusetts; Serono, Zug, Switzerland; Antigenics, New York, New York; Forest Laboratories, New York, New York; Genzyme, Cambridge, Massachusetts; and CaloSyn, Sharon, Massachusetts. Dr. Strand is a consultant for Abbott Immunology, Abbott Park, Illinois; Amgen, Albuquerque, New Mexico; AstraZeneca; Bayhill, Palo Alto, California; Biogenldec, Cambridge, Massachusetts; CanFite, Petah Tikva, Israel; Centocor, Horsham, Pennsylvania; Chelsea; Cypress Biosciences; EuroDiagnostica, Arnheim, The Netherlands; FibroGen, San Francisco, California; Forest Laboratories; GlaxoSmithKline, New York, New York; Genentech, South San Francisco, California; Human Genome Sciences, Rockville, Maryland; Lexicon Genetics, The Woodlands, Texas; Lux Biosciences, Jersey City, New Jersey; Merck Serono, Geneva, Switzerland; NicOx; Novartis; Novo Nordisk, Bagsværd, Denmark; Nuon, San Mateo, California; Ono Pharmaceticals, Lawrenceville, New Jersey; Pfizer; Proctor & Gamble, Cincinnati, Ohio; Roche; Sanofi-Aventis, Paris, France; Schering-Plough, Kenilworth, New Jersey; SKK, Nagoya, Japan; Savient; UCB, Berkshire, United Kingdom; and Xdx, South San Francisco, California. Dr. Strand is a member of the advisory Boards of Abbott Laboratories; Amgen; Centocor; Cypress Biosciences; Forest Laboratories; Idera, Cambridge, Massachusetts; Incyte Corporation; Novartis; Pfizer; Rigel; Crescendo, Palo Alto, California; Roche; Savient; Schering-Plough; UCB; and Xdx. Dr. White has received research funding from the National Institutes of Health, Bethesda, Maryland; Donaghue Medical Research Foundation, West Hartford, Connecticut; Novartis Research and Development. Dr. White has received educational funding from Teva Neurosciences, Kansas City, Missouri; and Pfizer. Dr. White is a consultant for Abbott Laboratories; Astellas Pharma US, Deerfield, Illinois; Boehringer-Ingelheim, Ingelheim, Germany; Forest Laboratories; NiCox; Rigel; Savient; Schering-Plough Research & Development; and Takeda Global Research Developments. Dr. Williams has received honoraria for speaking and contract payments for clinical trials from, is a consultant for, and is member of a data safety monitoring board for Pfizer. Dr. Williams was a presenter at a science advisory for a United States district court. Dr. Roberts has received honoraria for speaking from Merck, Whitehouse Station, New Jersey; Schering-Plough; AstraZeneca; and Novartis. All other individuals in a position to control content disclosed no relevant financial relationships.
PY - 2010/9/15
Y1 - 2010/9/15
UR - http://www.scopus.com/inward/record.url?scp=77956307423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956307423&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2010.04.006
DO - 10.1016/j.amjcard.2010.04.006
M3 - Article
C2 - 20816131
AN - SCOPUS:77956307423
SN - 0002-9149
VL - 106
SP - 873
EP - 884
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 6
ER -